{"id":"W4407265667","doi":"10.1093/ndt/gfaf022","title":"COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Relypsa; American Regent; Bayer, United Kingdom; Chugai Pharmaceutical; MannKind Corporation; Cytokinetics; Fresenius Medical Care North America; Astellas Pharma; Novo Nordisk; McMaster University; Daiichi-Sankyo; Impulse Dynamics; Idorsia Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Akebia Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Alexion Pharmaceuticals; Alnylam Pharmaceuticals; Bayer; Gilead Sciences; Bayer HealthCare; European Commission; Sanofi; Amgen; Pfizer","keywords":"Empagliflozin; Medicine; Placebo; Clinical endpoint; Internal medicine; Kidney disease; Confidence interval; Hazard ratio; Randomized controlled trial; Type 2 diabetes; Diabetes mellitus; Randomization; Endocrinology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007351325,0.0001247566,0.0005557787,0.0002367349,0.00003663979,0.000008101182,0.00002200255,0.0001122044,0.00001959246],"category_scores_gemma":[0.0003749518,0.00009617693,0.00003679864,0.0002462162,0.0001550476,0.00006280276,0.000006722839,0.0001185409,6.676153e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002620086,"about_ca_system_score_gemma":0.0001985271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003300334,"about_ca_topic_score_gemma":0.00008506135,"domain_scores_codex":[0.9986429,0.0003588283,0.00048324,0.0002412295,0.000122883,0.0001509153],"domain_scores_gemma":[0.9990225,0.000511243,0.0001238337,0.0001140237,0.00009381547,0.0001346269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09895038,0.0003889263,0.8431197,0.0008739913,0.0003793511,0.00007382721,0.0002217213,0.00005723703,0.0421562,0.0001899416,0.0000177639,0.01357096],"study_design_scores_gemma":[0.03221646,0.001782921,0.9129556,0.0003134328,0.002479462,0.00000356538,0.000004180239,0.04883016,0.001241487,0.00004899129,0.00004108874,0.00008268105],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976357,0.0003428392,0.0006619681,0.0007150741,0.0000641942,0.0005413779,0.00001807233,0.00001462221,0.000006122553],"genre_scores_gemma":[0.99806,0.001042792,0.0001003027,0.0004362253,0.00004349955,0.0000175792,0.0002813628,0.000007968668,0.00001019845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06983588,"threshold_uncertainty_score":0.3921981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02758190397293211,"score_gpt":0.3261872990378171,"score_spread":0.298605395064885,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}